TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03525782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cells
Description: Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T Cells
Description: Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAR-T combining PD-1 Knockout
Description: Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 knockout
Description: Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 knockout
Description: Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 mAb
Description: Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham control
Description: Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
Study: NCT04045080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMADEO
Description: AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OT Training
Description: training
Study: NCT01688141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced management
Description: Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
Study: NCT04338243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glumetinib
Description: Phase Ib is a dose escalation study, the initial dose of Glumetinib is 300mg, then will be escalated to 400mg，according to the result of Phase Ib， will confirm the RP2D
Study: NCT03827902

Intervention type: DEVICE
Intervention: Telcare 2.0 BGM
Description: Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
Study: NCT00401960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
Study: NCT03196375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLX-787-ODT (orally disintegrating tablet)
Description: FLX-787-ODT taken three times daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ODT
Description: Placebo ODT taken three times daily for 28 days
Study: NCT03697564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV on days 1, 8, and 15 Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
Description: 480mg IV on Day 1 Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: 4mg/kg IV on day 1 and 15 Q4W
Study: NCT03436199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102, 137 mg
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102, 274 mg
Description: Oral capsules

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Oral capsules
Study: NCT03059121

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-energy X-ray absorptiometry
Study: NCT02959515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capnothorax
Description: Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capnothorax and CPAP
Description: Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager.
Study: NCT01142765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 MSP1, MVA MSP1, challenge
Description: 1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1, MVA AMA1, challenge
Description: 1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge
Description: 1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge
Description: 1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sporozoite challenge
Description: Non-vaccinated controls for sporozoite challenge
Study: NCT02415062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 23mg/day for 24 weeks versus 10mg/day for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 23mg/day for 24 weeks versus 10mg/day for 24 weeks
Study: NCT02411318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProLab 200mg caffeine capsule
Description: Participants will swallow one ProLab caffeine 200mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProLab 200mg caffeine capsule
Description: Participants will swallow one ProLab caffeine 200mg tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion
Description: Participants will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose Tolerance Drink
Description: Participants will consume 100 grams of glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose Tolerance Drink
Description: Participants will consume 100 grams of glucose
Study: NCT04952207

Intervention type: DRUG
Intervention: Direct-acting antiviral agents
Description: The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
Study: NCT04673435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PermeaDerm for temporary coverage
Description: See above

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FHCA for temporary coverage
Description: See above

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PermeaDerm over autograft
Description: See above

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FHCA over autograft
Description: see above
Study: NCT04592289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full bowel preparation
Description: MBP+OA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical bowel preparation only
Description: MBP
Study: NCT02464644

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
Study: NCT00853515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid resuscitation
Description: Targeted, weight-based fluid resuscitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid resuscitation
Description: Targeted, weight-based fluid resuscitation
Study: NCT00851773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.1 mg once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.2 mg once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.4 mg once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.1 mg once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.2 mg once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.4 mg once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
Study: NCT03438058

Intervention type: OTHER
Intervention: Graft survival and/or Rejection appearance

Intervention type: OTHER
Intervention: Graft survival and/or Rejection appearance
Study: NCT00043186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70 mg tablets
Study: NCT03884062

Intervention type: DRUG
Intervention: DAAs
Description: lab, U/S, Fibroscan \& CT if needed
Study: NCT03140566

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of the inferior vena cava diameter
Description: Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index \>50% in addition to relief of symptoms and signs of congestion before discharge.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound evaluation of the inferior vena cava diameter
Description: Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
Study: NCT01489917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patent hemostasis and heparin
Description: Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
Study: NCT00369603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Razadyne ER
Description: 4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept
Description: 8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
Study: NCT00082641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus p53 vaccine
Description: Given subcutaneously on one of two schedules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus p53 vaccine
Description: Given subcutaneously on one of two schedules
Study: NCT00487318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: peginterferon/RBV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvastatin
Description: Add fluvastatin at 20-40 mg/day to standard of care
Study: NCT03957408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Stimuli
Description: Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
Study: NCT00510198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Compass with OptiVol Fluid Status Monitoring
Description: Review of Cardiac Compass with OptiVol Fluid Status Monitoring

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care alone (clinical assessment)
Description: Clinical assessment utilizing standard of care, alone.
Study: NCT02605278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical program for pain and depression
Description: Already described

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Care as usual
Study: NCT04071509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Lung Biopsy
Description: Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
Study: NCT00637247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon in combination with gemcitabine
Description: 875 mg/m\^2 imexon IV + 1000 mg/m\^2 gemcitabine IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imexon placebo + gemcitabine
Description: imexon placebo IV + 1000 mg/m\^2 gemcitabine IV
Study: NCT00195442

Intervention type: DRUG
Intervention: Moroctocog alfa
Description: Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT01863797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expectant mamagement
Study: NCT04342598

Intervention type: OTHER
Intervention: Serum Vitamin D
Description: Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.

Intervention type: OTHER
Intervention: Serum Vitamin D
Description: Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.

Intervention type: OTHER
Intervention: Serum Vitamin D
Description: Primary exposure assessed will be serum vitamin D (25(OH)D). Diet will also be assessed via Food Frequency Questionnaire.
Study: NCT04070729

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Localized subgingival application
Study: NCT03438058

Intervention type: OTHER
Intervention: Graft survival and/or Rejection appearance
Study: NCT04070729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Localized subgingival application

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Localized subgingival application
Study: NCT02830009

Intervention type: OTHER
Group type: OTHER
Intervention: Urines samples
Description: 24-hour urines will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Urines samples
Description: 24-hour urines will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Urines samples
Description: 24-hour urines will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Urines samples
Description: 24-hour urines will be collected

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Study: NCT04338191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI adjuvant chemotherapy
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 adjuvant chemotherapy
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles
Study: NCT03391232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyPEPI1018 CRC Vaccine
Description: Colorectal Cancer Vaccine
Study: NCT00893906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal trivalent inactivated influenza vaccine
Description: vaccine to be used according to marketed dosage and frequency

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated polio vaccine
Description: vaccine to be used according to marketed dosage and frequency
Study: NCT02286375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intervention group
Description: A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
Study: NCT02722161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BI 1482694
Study: NCT03050541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02022475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 100 000 units oral vitamin D as 2 capsules 50 000 units each

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 placebo capsules will be applied as a single dose